Food and Drug Administration (FDA) Archives - Cannabis Business Executive - Cannabis and Marijuana industry news

Delta-8 marijuana products can be dangerous, health officials warn

CDC and FDA officials said they had received reports of adverse events tied to the products. U.S. health officials are warning about the potential dangers of "delta-8 THC," a compound derived from marijuana, after seeing an increase in hospitalizations tied…

Class Actions Increasingly Targeting Cannabis Companies

by Julie Hussey, Barak Cohen, Tommy Tobin Recent years have seen increased growth for cannabis companies, especially as the market for THC products continues to expand. But this growth brings with it increasing scrutiny of the industry by regulators and…

Congress Must Chart a Safe Path Forward for CBD and Hemp Products

With the passing of the 2018 U.S. Farm Bill, the production of industrial hemp and its derivative products, such as CBD, became legal at the Federal level. CBD, unlike THC, produces no psychoactive effect (or “high”) and many studies have…

Maturing the Infused Beverage and Edibles Market Means Prioritizing QC Protocols

May 6, 2021
Loni Mowbray
Lab Testing, Science and Technology, Standards and Certification
0 Comments

Over the past few years, many consumers have come to embrace CBD, THC, and other cannabinoids as functional ingredients in beverages and edibles, yet the food and beverage industry as a whole has been slow to accept this trend. For…

CBD Advertising Proceed with Caution to Avoid Confusion, Stay Out of State AG Crosshairs

by Meghan Stoppel and Mira Baylson Consumers today report record-levels of stress and anxiety related to COVID. To alleviate these feelings, consumers are turning to exercise, diet changes, and dietary supplements. Cannabidiol (CBD) products in particular are rising in popularity.…

Will the FTC Adopt Less Stringent Substantiation Requirements for CBD Claims?

by Natalie Bougenies, Attorney at Harris Bricken If you follow our blog, you know we keep a close eye on enforcement actions taken by the Food and Drug Administration (the FDA) and the Federal Trade Commission (the FTC or the…

The “Right to Try” Psilocybin and New Drug Therapies

by Vince Sliwoski, Attorney at Harris Bricken I was talking to another lawyer about last week’s vote by Oregonians to legalize psilocybin therapy here in the state. We discussed how licensed facilities won’t be up and running for a few…

Federal Policy on Hemp CBD Is Taking Shape: What Needs to Be Addressed?

By Daniel Shortt, Attorney @ Harris Bricken This is the first post in a two-part series. Last week, the Food and Drug Administration (FDA) submitted a CBD enforcement policy to the White House. We do not yet have the text…

Hemp-Derived THC Products: Legal or Loophole?

By Ian A. Stewart, Devon Mills and Neil Willner Hemp-derived CBD products have exploded onto the market since Congress removed hemp from the Controlled Substances Act (CSA) in the 2018 Farm Bill. Now, new hemp-derived products are emerging that contain…

Hemp CBD: Even Without FDA Regulations, Class Action Suits May Go Forward

by Jesse Mondry, Attorney at Harris Bricken A couple of months ago we reported on a decision in the Southern District of Florida in which the court stayed a putative class action lawsuit against a seller of cannabidiol (CBD) products…

Reading the Tea Leaves: Looking at the History of Hemp and CBD to Predict the Future

By Justin Walsh[1] It’s an exciting time to be in hemp and CBD! I have attended and spoken at several conferences over the last year. I have been in places as diverse as Seattle, Denver, Dallas, and Orlando. The products…

BREAKING NEWS: FDA and USDA Start Making Sense on Hemp CBD

By Daniel Shortt, Attorney @ Harris Bricken According to Hemp Industry Daily reporter Laura Drotleff, it was an eventful week for hemp regulation at the National Association of State Department of Agriculture (NASDA) meeting in Arlington, Virginia. Drotleff reported on two…

Quality

Using Quality as a Competitive Differentiator in the Cannabis Industry

February 3, 2020
Susan Gunelius
Best Practices, Compliance and Regulations, News & Insights, Standards and Certification
0 Comments

In the aftermath of the recent vaping epidemic, cannabis consumers and businesses are paying more attention to quality than ever. For the sake of the industry’s long-term growth, let’s hope that concern translates into action with both time and monetary…

Will the FDA’s Ban on E-Cigarettes Affect CBD Vaping Devices?

By Nathalie Bougenies, Attorney at Harris Bricken On January 2, the Food and Drug Administration (“FDA”) issued non-binding guidance (“Guidance”) in which the agency explains how it intends to prioritize enforcement actions to tackle the growing increase in youth use of…

Top 4 Predictions for Hemp and Hemp CBD in 2020

By Griffen Thorne, Attorney at Harris Bricken 2019 was, to put it lightly, an intense year for the hemp and hemp-derived cannabidiol (“Hemp CBD”) industries in the United States. We saw the implementation of the 2018 Farm Bill, strongly worded…

Page 1
Page 2
Page 3
Next